vs
Side-by-side financial comparison of CEVA INC (CEVA) and KalVista Pharmaceuticals, Inc. (KALV). Click either name above to swap in a different company.
CEVA INC is the larger business by last-quarter revenue ($27.0M vs $13.7M, roughly 2.0× KalVista Pharmaceuticals, Inc.).
CEVA Logistics is a global logistics and supply chain company that operates both freight management and contract logistics. It was purchased by the CMA CGM group in 2019. Since this purchase, CMA CGM has acquired other logistics and transportation companies to merge with and develop CEVA Logistics, such as Ingram Micro Commerce & Lifecycle Services and GEFCO.
KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel oral serine protease inhibitor therapies. Its core pipeline addresses unmet medical needs for rare and inflammatory diseases including hereditary angioedema and diabetic macular edema, with primary target markets in North America and Europe.
CEVA vs KALV — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $27.0M | $13.7M |
| Net Profit | — | $-49.5M |
| Gross Margin | 86.2% | 91.0% |
| Operating Margin | -5.0% | -336.3% |
| Net Margin | — | -361.4% |
| Revenue YoY | 11.5% | — |
| Net Profit YoY | — | -17.1% |
| EPS (diluted) | — | $-0.92 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $27.0M | — | ||
| Q4 25 | $31.3M | — | ||
| Q3 25 | $28.4M | $13.7M | ||
| Q2 25 | $25.7M | — | ||
| Q1 25 | $24.2M | — | ||
| Q4 24 | $29.2M | — | ||
| Q3 24 | $27.2M | $0 | ||
| Q2 24 | $28.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-1.1M | — | ||
| Q3 25 | $-2.5M | $-49.5M | ||
| Q2 25 | $-3.7M | — | ||
| Q1 25 | $-3.3M | — | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $-1.3M | $-40.4M | ||
| Q2 24 | $-291.0K | — |
| Q1 26 | 86.2% | — | ||
| Q4 25 | 88.1% | — | ||
| Q3 25 | 88.0% | 91.0% | ||
| Q2 25 | 86.2% | — | ||
| Q1 25 | 85.6% | — | ||
| Q4 24 | 88.5% | — | ||
| Q3 24 | 85.4% | — | ||
| Q2 24 | 89.7% | — |
| Q1 26 | -5.0% | — | ||
| Q4 25 | -1.3% | — | ||
| Q3 25 | -7.3% | -336.3% | ||
| Q2 25 | -17.5% | — | ||
| Q1 25 | -18.1% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | -9.6% | — | ||
| Q2 24 | -0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | -3.5% | — | ||
| Q3 25 | -8.8% | -361.4% | ||
| Q2 25 | -14.4% | — | ||
| Q1 25 | -13.7% | — | ||
| Q4 24 | -5.9% | — | ||
| Q3 24 | -4.8% | — | ||
| Q2 24 | -1.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.92 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.87 | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $21.4M | $243.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $338.2M | $17.0M |
| Total Assets | $388.2M | $339.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $21.4M | — | ||
| Q4 25 | $40.6M | — | ||
| Q3 25 | $17.3M | $243.5M | ||
| Q2 25 | $29.1M | — | ||
| Q1 25 | $18.8M | — | ||
| Q4 24 | $18.8M | — | ||
| Q3 24 | $13.2M | $31.8M | ||
| Q2 24 | $25.0M | — |
| Q1 26 | $338.2M | — | ||
| Q4 25 | $336.5M | — | ||
| Q3 25 | $268.7M | $17.0M | ||
| Q2 25 | $265.9M | — | ||
| Q1 25 | $269.1M | — | ||
| Q4 24 | $266.6M | — | ||
| Q3 24 | $265.8M | $172.8M | ||
| Q2 24 | $263.8M | — |
| Q1 26 | $388.2M | — | ||
| Q4 25 | $388.3M | — | ||
| Q3 25 | $306.0M | $339.9M | ||
| Q2 25 | $302.8M | — | ||
| Q1 25 | $310.0M | — | ||
| Q4 24 | $308.9M | — | ||
| Q3 24 | $304.9M | $200.2M | ||
| Q2 24 | $300.4M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CEVA
| Licensing and related revenues | $17.8M | 66% |
| Royalties | $9.2M | 34% |
KALV
Segment breakdown not available.
